DDInter557 DDInter1665
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Salivary hypersecretion {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Verapamil
Verapamil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Salivary hypersecretion {u} (Side Effect) is caused by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Lacrimal disorder
Lacrimal disorder {u} (Side Effect) is caused by {v} (Compound) Pregabalin
Pregabalin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Ventricular tachycardia
Ventricular tachycardia {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Ventricular fibrillation
Ventricular fibrillation {u} (Side Effect) is caused by {v} (Compound) Paliperidone
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Dihydroergotamine (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may lead to a major life threatening interaction when taken with Sibutramine
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Verapamil (Compound) and Verapamil may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Dihydroergotamine (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Dihydroergotamine (Compound) causes Lacrimal disorder (Side Effect) and Lacrimal disorder (Side Effect) is caused by Pregabalin (Compound) and Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Dihydroergotamine (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Ergotamine (Compound) and Ergotamine may lead to a major life threatening interaction when taken with Sibutramine
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Dihydroergotamine (Compound) causes Ventricular fibrillation (Side Effect) and Ventricular fibrillation (Side Effect) is caused by Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine